Want to take quizzes and track your credits?
What is the association of legal market cannabis flower and concentrates with cannabis intoxication and neurobehavioral impairment?
In this cohort study of 121 cannabis flower users and concentrate users randomly assigned to higher- vs lower-THC products within user groups, use of legal market cannabis concentrates (ranging from 70%-90% tetrahydrocannabinol [THC]) produced significantly higher THC blood plasma levels compared with use of legal market cannabis flower (ranging from 16%-24% THC). Despite differences in THC exposure, flower and concentrate users showed similar neurobehavioral patterns after acute cannabis use and the domains of verbal memory and proprioception-focused postural stability for both groups were associated with THC.
Use of cannabis concentrates was associated with higher THC exposure and potentially greater risk, but differences in short-term subjective and neurobehavioral impairments did not track specifically with strength of the cannabis consumed.
The rapidly growing legal cannabis market includes new and highly potent products, the effects of which, to our knowledge, have not previously been examined in biobehavioral research studies because of federal restrictions on cannabis research.
To use federally compatible, observational methods to study high-∆9-tetrahydrocannabinol (THC) legal market forms of cannabis.
Design, Setting, and Participants
In this cohort study with a between-groups design that was conducted in a community and university setting, cannabis flower users and concentrate users were randomly assigned to higher- vs lower-THC products within user groups. Participants completed a baseline and an experimental mobile laboratory assessment that included 3 points: before, immediately after, and 1 hour after ad libitum legal market flower and concentrate use. Of the 133 individuals enrolled and assessed, 55 regular flower cannabis users (41.4%) and 66 regular concentrate cannabis users (49.6%) complied with the study’s cannabis use instructions and had complete data across primary outcomes.
Flower users were randomly assigned to use either 16% or 24% THC flower and concentrate users were randomly assigned to use either 70% or 90% THC concentrate that they purchased from a dispensary.
Main Outcomes and Measures
Primary outcome measures included plasma cannabinoids, subjective drug intoxication, and neurobehavioral tasks testing attention, memory, inhibitory control, and balance.
A total of 121 participants completed the study for analysis: 55 flower users (mean [SD] age, 28.8 [8.1] years; 25 women [46%]) and 66 concentrate users (mean [SD] age, 28.3 [10.4] years; 30 women [45%]). Concentrate users compared with flower users exhibited higher plasma THC levels and 11-hydroxyΔ9-THC (THC’s active metabolite) across all points. After ad libitum cannabis administration, mean plasma THC levels were 0.32 (SE = 0.43) μg/mL in concentrate users (to convert to millimoles per liter, multiply by 3.18) and 0.14 (SE = 0.16) μg/mL in flower users. Most neurobehavioral measures were not altered by short-term cannabis consumption. However, delayed verbal memory (F1,203 = 32.31; P < .001) and balance function (F1,203 = 18.88; P < .001) were impaired after use. Differing outcomes for the type of product (flower vs concentrate) or potency within products were not observed.
Conclusions and Relevance
This study provides information about the association of pharmacological and neurobehavioral outcomes with legal market cannabis. Short-term use of concentrates was associated with higher levels of THC exposure. Across forms of cannabis and potencies, users’ domains of verbal memory and proprioception-focused postural stability were primarily associated with THC administration.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: March 11, 2020.
Corresponding Author: L. Cinnamon Bidwell, PhD, Institute of Cognitive Science, UCB 344, Boulder, CO 80309 9(firstname.lastname@example.org).
Published Online: June 10, 2020. doi:10.1001/jamapsychiatry.2020.0927
Author Contributions: Drs Bidwell and Hutchison had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Bidwell, Tracy, Bryan, Hutchison.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Bidwell, Ellingson, Karoly, YorkWilliams, Hitchcock, Tracy, Bryan, Hutchison.
Critical revision of the manuscript for important intellectual content: Bidwell, Ellingson, YorkWilliams, Hitchcock, Tracy, Klawitter, Sempio, Bryan, Hutchison.
Statistical analysis: Bidwell, Ellingson, Karoly, YorkWilliams, Hitchcock, Tracy, Bryan, Hutchison.
Obtained funding: Bidwell, Bryan, Hutchison.
Administrative, technical, or material support: Bidwell, Hitchcock, Tracy, Klawitter, Hutchison.
Supervision: Bidwell, Tracy, Hutchison.
Conflict of Interest Disclosures: Dr Bidwell reported grants from the National Institutes of Health (NIH)/National Institute on Drug Abuse and the State of Colorado Department of Public Health and Environment during the conduct of the study. Dr Ellingson reported grants from the NIH during the conduct of the study. Dr Klawitter reported grants from the Colorado Department of Public Health and Environment and NIH during the conduct of the study. Dr Sempio reported grants from the Colorado Department of Public Health and Environment and the NIH during the conduct of the study. Dr Bryan reported grants from the NIH and State of Colorado during the conduct of the study. No other disclosures were reported.
Funding/Support: Funding for this study was provided by grants from the NIH (DA039707 to Dr Hutchison) and Colorado Department of Public Health and Environment (96947 to Dr Bidwell).
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
You currently have no searches saved.
You currently have no courses saved.